TY - JOUR
T1 - Topical Erythropoietin for Treatment of Scleral Necrosis
AU - Feizi, Sepehr
AU - Alemzadeh-Ansari, Mohammadhasan
AU - Baradaran- Rafii, Alireza
AU - Esfandiari, Hamed
AU - Kheirkhah, Ahmad
N1 - Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2021
Y1 - 2021
N2 - Purpose: To investigate the safety and efficacy of topical erythropoietin for the treatment of scleral necrosis. Methods: This study enrolled eight consecutive patients with scleral necrosis due to previous ocular surgery, rheumatoid arthritis-associated necrotizing anterior scleritis, and thermal and chemical burns. Conventional treatments failed to heal avascular scleral lesions in all eyes. Patients were treated with topical erythropoietin (3000 IU/mL) four times a day. Results: The mean patient age was 37.6 ± 15.5 years. The interval between the development of scleral necrosis and initiation of topical erythropoietin was 25.6 ± 12.0 days. The necrotic sclera completely healed within 31.9 ± 16.9 days in all patients. The avascular lesions did not recur, and there was no evidence of side effects during the study. Conclusion: Our results showed that topical erythropoietin could be safely used to manage scleral necrosis. Randomized clinical trials are needed to further explore the efficacy of this intervention in patients with avascular scleral lesions.
AB - Purpose: To investigate the safety and efficacy of topical erythropoietin for the treatment of scleral necrosis. Methods: This study enrolled eight consecutive patients with scleral necrosis due to previous ocular surgery, rheumatoid arthritis-associated necrotizing anterior scleritis, and thermal and chemical burns. Conventional treatments failed to heal avascular scleral lesions in all eyes. Patients were treated with topical erythropoietin (3000 IU/mL) four times a day. Results: The mean patient age was 37.6 ± 15.5 years. The interval between the development of scleral necrosis and initiation of topical erythropoietin was 25.6 ± 12.0 days. The necrotic sclera completely healed within 31.9 ± 16.9 days in all patients. The avascular lesions did not recur, and there was no evidence of side effects during the study. Conclusion: Our results showed that topical erythropoietin could be safely used to manage scleral necrosis. Randomized clinical trials are needed to further explore the efficacy of this intervention in patients with avascular scleral lesions.
KW - chemical burns
KW - necrotizing anterior scleritis
KW - scleral necrosis
KW - surgically-induced necrotizing scleritis
KW - topical erythropoietin
UR - http://www.scopus.com/inward/record.url?scp=85107727910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107727910&partnerID=8YFLogxK
U2 - 10.1080/09273948.2021.1934485
DO - 10.1080/09273948.2021.1934485
M3 - Article
AN - SCOPUS:85107727910
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
SN - 0927-3948
ER -